What’s Going On With Sea Stock Wednesday?

Sea Limited (NYSE: SE) stock is trading flat, weighed by the dismal second-quarter results and analyst re-ratings.

Sea Limited (NYSE:SE) stock is trading flat, weighed by the dismal second-quarter results and analyst re-ratings.

On Tuesday, Sea reported second-quarter FY23 revenue growth of 5.2% year-on-year to $3.096 billion, missing the consensus of $3.420 billion. Adjusted EPS of $0.54 missed the consensus of $0.69. 

Digital Entertainment revenue decreased 41.2% Y/Y to $529.4 million, E-commerce and other services revenue increased 20.6% Y/Y to $2.1 billion, and Digital Financial Services revenue grew 53.4% Y/Y to $427.9 million.

Goldman Sachs analyst Pang Vittayaamnuaykoon reiterated a Buy on Sea with a price target of $78.

 E-commerce adjusted EBITDA contracted Q/Q to $150 million as expected, but the magnitude of the S&M spend still exceeded his expectations, leading to the miss.

Management commentary indicated a significant shift towards a growth-led strategy with e-commerce/group-level EBITDA potentially dipping back to negative territory. 

Shopee looks to reinvest in new opportunities and turn from defensive to offensive mode to gain share as peers rationalize, though self-sufficiency is to be maintained. 

Pang now expects EBITDA for Shopee to return to the red before returning to positive territory in the second half.

Early signs of a growth recovery with orders +10% Q/Q will persist into the rest of the year.

Gaming delivered a substantial EBITDA margin beat on higher self-developed game mix and cost efficiency. 

The analyst acknowledged the risk of heightened near-term volatility given limited visibility on the magnitude of Shopee’s spending, which may limit the share price rebound in the near term. 

Pang expects revenue of $12.18 billion in FY23 (prior $12.77 billion), $13.74 billion in FY24 (prior $15.15 billion), and $16.44 billion in FY25 (prior $17.99 billion).

Pang models EPS of $1.22 in FY23 (prior $2.30), $1.54 in FY24 (prior $4.51), and $$3.37 in FY25 (prior $6.50).

Citigroup analyst Alicia Yap downgraded Sea from Buy to Neutral and a $50 price target.

B of A Securities analyst Sachin Salgaonkar maintained Sea with a Neutral and lowered the price target from $73 to $53.

Bernstein analyst Venugopal Garre maintained Sea with an Outperform and lowered the price target from $90 to $70.

Price Action: SE shares traded higher by 0.30% at $40.70 on the last check Wednesday.

Total
0
Shares
Related Posts
Read More

CBD-Focused Pharma Co. Innocan Reveals 433% YoY Increase In 2023 Revenue As It Pursues FDA Approval

Cannabinoid-focused pharmaceutical company Innocan Pharma Corp expects preliminary revenues of $4.89m in Q4 of fiscal 2023, representing a YoY increase of 331%. It said preliminary revenues are expected to be at least $13.6m for the whole of the fiscal year, a 433% YoY increase. Its subsidiary B.I. Sky Global drove the increase in sales. Innocan is currently pursuing FDA approval for its human pharmaceutical applications following successful pre-clinical trials, and the company expects pre-investigational new drug applications to be submitted to the FDA before the end of the month. Innocan has developed a long-lasting and therapeutic liposomal formulation for CBD called LPT Solution, which administers injectable CBD encapsulated in liposomes to achieve long-lasting therapeutic levels of CBD in the body. The company said the technology creates a more effective and prolonged therapeutic effect. Innocan plans to test the LPT platform on a new animal species in the near future.

CSE:INNO